Cytokinetics, Incorporated
CYTK
Classifica tra le azioni
#2284
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on... Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in heart failure with severely reduced ejection fraction. In addition, the company is involved in developing and Ulacamten, a novel, selective, oral, and small molecule cardiac myosin inhibitor designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction in Phase 1 clinical trials; and CK-089, a fast skeletal muscle troponin activator in Phase 1 clinical trials. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.
Prezzo delle azioni
$62.83
Capitalizzazione di mercato
$8.73B
Variazione (1 giorno)
-1.75%
Variazione (1 anno)
8.74%
Paese
US
Scambia Cytokinetics, Incorporated (CYTK)
Categoria
Healthcare
Storico del prezzo dell'azione per Cytokinetics, Incorporated (CYTK)
Prezzo di chiusura più alto: $62.96 il 2026-10-01
Prezzo di chiusura più basso: $97.08 il 2004-04-01
Prezzo di chiusura più basso: $97.08 il 2004-04-01
Storico del prezzo dell'azione di Cytokinetics, Incorporated dal 2004 al 2026
Andamento annuale del prezzo dell'azione
| Anno | Performance |
|---|---|
| 2026 (TTM) | 8.63% |
| 2025 | 28.55% |
| 2024 | 11.95% |
| 2023 | 4.76% |
| 2022 | 4.97% |
| 2021 | 101.81% |
| 2020 | 97.15% |
| 2019 | 42.08% |
| 2018 | -14.22% |
| 2017 | -29.65% |
| 2016 | 4.66% |
| 2015 | 114.65% |
| 2014 | -19.66% |
| 2013 | 59.81% |
| 2012 | -32.39% |
| 2011 | -55.97% |
| 2010 | -23.56% |
| 2009 | 26.62% |
| 2008 | -55.25% |
| 2007 | -26.58% |
| 2006 | -3.72% |
| 2005 | -20.38% |
| 2004 | 0.00% |
Prezzo dell'azione per aziende simili o concorrenti
| Azienda | Prezzo dell'azione | Variazione 1a% | Il paese |
|---|---|---|---|
| $527.18 | 23.67% |
US
|
|
| $251.29 | 814.11% |
US
|
|
| $136.62 | -4.51% |
AU
|
|
| $890.85 | 6.72% |
NL
|
|
| $752.87 | 7.40% |
CH
|
